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Neuromuscular Disorders 24 (2014) 201–206Abstract
The Performance of Upper Limb was speciﬁcally designed to assess upper limb function in Duchenne muscular dystrophy. The aim of
this study was to assess (1) a cohort of typically developing children from the age of 3 years onwards in order to identify the age when the
activities assessed in the individual items are consistently achieved, and (2) a cohort of 322Duchenne children and young adults to establish
the range of ﬁndings at diﬀerent ages. We collected normative data for the scale validation on 277 typically developing subjects from 3 to
25 years old.A full scorewas consistently achieved by the age of 5 years. In theDuchenne cohort therewas early involvement of the proximal
muscles and a proximal to distal progressive involvement. The scalewas capable ofmeasuring small distalmovements, related to activities of
daily living, even in the oldest and weakest patients. Our data suggest that the assessment can be reliably used in both ambulant and non
ambulant Duchenne patients in a multicentric setting and could therefore be considered as an outcome measure for future trials.
 2013 The Authors. Published by Elsevier B.V.
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In the last fewyears a number of therapeutical approaches
have become available for Duchenne muscular dystrophy
(DMD). The rapidly increasing number of ongoing or
planned clinical trials has highlighted the need to identify
reliable outcome measures [1,2]. So far the trials have
mainly targeted young ambulant DMD boys [3,4], using
the 6 min walk test (6MWT) [5,6] or other functional
measures such as timed tests or the North Star
Ambulatory Assessment (NSAA). In order to have the
possibility to also include non ambulant DMD boys and
adults in the forthcoming trials, and, more generally, to
have measures that could be used across spectrum of
abilities, allowing to follow the boys who may lose
ambulation during a trial, there has been increasing
attention on assessments of upper limb function [7]. An
international Clinical Outcomes Group consisting of
clinicians, scientists, patient advocacy groups and
industries worked together to develop the Performance of
the Upper Limb (PUL), a tool speciﬁcally designed for
assessing upper limb function in ambulant and non-
ambulant DMD patients [8–10]. The development of the
PUL was based on a conceptual framework reﬂecting the
progression of weakness and natural history of functional
decline in DMD. The DMD boys and their families were
involved iteratively throughout the process, providing
comments on the relevance of individual PUL items to
abilities of daily living and on their clinical
meaningfulness. Modern psychometric methods (Rasch
analysis) were used to improve robust internal reliability,
validity, and hierarchical scalability [10].
All the tasks included in the PUL were selected including
activities of daily living that should be performed even by
preschool children. We were postulating that typically
developing children of 3–4 years of age would pass all the
items and complete the scale with a plateau of scores in
older children. In order to avoid ceiling eﬀect we also
included timed items evaluating the speed to perform some
tasks such as stacking cans.
The aim of this cross sectional study was to perform PUL
in DMD boys and adults and in typically developing boys
and male adults in order to observe the distribution of
scores and the suitability of the scale at diﬀerent ages. More
speciﬁcally we wished to establish (a) the age when typically
developing children are able to complete the assessment (b)
the proﬁle of scores in DMD boys and adults at diﬀerent
ages and their relationship with the scores found in
typically developing subjects. We also wished to investigate
whether the timed items could provide additional value to
the scale avoiding possible ceiling eﬀect.
2. Subjects and methods
The study is part of a longitudinal multicentric study
aimed at establishing changes in upper limb function in
DMD. The study was approved by the Ethics committeein each centre. As part of this study all the Italian
tertiary care centers for neuromuscular disorders
consecutively enrolled 322 DMD patients (mean age 12.7;
range 4.1–35.1) attending their routine follow up clinics
between September 2012 and April 2013.
In order to establish the earliest age when the PUL can be
completed, 277 typically developing boys and young adults
were also examined by six examiners from 3 centers (Rome,
Milan, Pisa) involved in the DMD study. In the ﬁrst phase
we systematically assessed children up to the age of 5,
assessing 47 children between 3 and 5 years. Following the
observation that there was already a plateau of full scores
by 5 years, we also performed the PUL in 230 boys and
young adults between the age of 5 and 25 in order to
conﬁrm the plateau in subjects older than 5 years and
observe possible variations of the timed items with age.2.1. PUL
The PUL includes 22 items (online appendix) with an
entry item to deﬁne the starting functional level, and 21
items subdivided into shoulder level (4 items), middle
level (9 items) and distal level (8 items) dimension [10].
For weaker patients a low score on the entry item means
high level items do not need to be performed. Scoring
options vary across the scale between 0–1 and 0–6
according to performance. Each dimension can be scored
separately with a maximum score of 16 for the shoulder
level, 34 for the middle level, and 24 for the distal level.
A total score can be achieved by adding the three level
scores (max global score 74).2.2. Training sessions
At least one therapist from each group attended a ﬁrst
training session where a senior physiotherapist (ESM)
presented the PUL with item description, scoring system
and demonstrated scale administration through patient
videos to outline any scoring shortcomings or issues. All
participants were subsequently asked to video a patient
assessment. After a review with the senior physiotherapist
and the resolution of possible scale administration issues,
the 14 clinical evaluators were then asked to score three
more videos to outline any diﬃculties and possible lack
of agreement in scores and to determine inter-rater
reliability. The results showed an ICC of 0.96.
Three examiners (ESM, LF, RDS) also assessed six
children twice with intervals ranging from 1 h to 1 week
with identical results between the ﬁrst and the second
assessment in all six.2.3. Statistical analysis
Non-linear relationships with age were preliminarily
assessed by a visual inspection of the plots and then
analyzed using a piecewise linear regression. A piecewise
M. Pane et al. / Neuromuscular Disorders 24 (2014) 201–206 203regression model allows for changes in slope and consists
of two or more straight line segments.
Following recent evidence that when examined on the
6MWT, the NSAA and timed items, the slope of
deterioration in DMD boys occurs after the age of 7
[11,12], we also arbitrarily subdivided the cohort in very
young boys (<5), 5–7.9, 8–12.9, 13–21 and above 21 years.3. Results
3.1. Typically developing boys and young adults
In this cohort all were able to complete the assessment
and none refused to perform it. All but 27 (>90%) had a
full score or one point less (73 or 74 out of 74). The 27
boys who had a score lower than 73 were all younger
than 5 years and the items that did not have a full score
were stacking cans as the children were too short to stack
the last cans remaining seated and holding the bigger
weights, opening a Ziploc container or tearing a piece of
paper because of the small hand size. The sub scores ofFig. 1. Distribution of scores in typically developing (green) and DM
Fig. 2. Total scores in ambulant (blue) and non ambutypically developing and DMD subjects subdivided
according to functional levels (shoulder, middle and
distal) are shown in Fig. 1.3.2. DMD patients
The total scores ranged between 0 and 74 with a
progressive decrease after the age of 8. (Fig. 2 and Table 1).
3.3. Shoulder level
The results of the piecewise regression analysis showed
an improvement of scores in the younger DMD children.
The point of slope change was between 9 and 10 years
with and a sharp decline after that with very low scores
(2 or less) by the age of 16 years (Fig. 1a).
3.4. Middle level
There was an improvement of scores in the younger
children and the point of slope change was between 8D (red) subjects at shoulder (a), middle (b) and distal (c) level.
lant (red) DMD patients plotted according to age.
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(Fig. 1b).3.5. Distal level
There was an improvement of scores in the younger
children with a ﬁrst point of slope change around 6 years,Table 1
Distribution of total scores and of the subscores in the three levels subdivided
Age (yrs) Shoulder Mid level
Control (n = 277) DMD (n = 322) Control
<5 (n = 47) (n = 11) (n = 47)
Range 12–16 8–16 28–34
Mean (SD) 14.8 (1.72) 11.81 (2.27) 31.8 (1.9)
5–7, 9 (n = 66) (n = 62) (n = 66)
Range 16 3–16 33–34
Mean (SD) 15.81 (0.83) 13.69 (2.71) 33.8 (0.85)
8–12, 9 (n = 107) (n = 112) (n = 107)
Range 16 0–16 34
Mean (SD) 16 (0) 11.01 (5.92) 34 (0)
13–21, 9 (n = 42) (n = 115) (n = 42)
Range 16 0–16 34
Mean (SD) 16 (0) 3.2 (5.79) 34 (0)
>21 (n = 15) (n = 22) (n = 15)
Range 16 0–3 34
Mean (SD) 16 (0) 0.13 (0.63) 34 (0)
Fig. 3. Mean and 95% conﬁdence intervals of timed activities (in seconds) in ty
L. Note the overlap in the younger subjects and a more obvious divergence ofollowed by a mild decline and a second point change
associated with a sharper decline around 16 years (Fig. 1c).3.6. Timed items
Fig. 3 shows the distribution of the time spent to
perform the individual items (I, J, K, L) in typicallyaccording to age groups in typically developing and DMD subjects.
Distal Total
DMD Control DMD Control DMD
(n = 11) (n = 47) (n = 11) (n = 47) (n = 11)
27–34 19–24 19–24 60–74 58–73
32.09 (2.3) 23 (1.35) 22.27 (1.67) 69.68 (4.23) 66.18 (4.79)
(n = 62) (n = 66) (n = 62) (n = 66) (n = 62)
24–34 23–24 19–24 73–74 56–74
33.08 (1.41) 23.92 (0.26) 23.46 (0.88) 73.36 (1.21) 70.27 (3.79)
(n = 112) (n = 107) (n = 112) (n = 107) (n = 112)
0–34 23–24 0–24 73–74 0–74
30.79 (7.21) 23.96 (0.19) 22.99 (2.5) 73.96 (0.25) 64.81 (13.94)
(n = 115) (n = 42) (n = 115) (n = 42) (n = 115)
0–34 23–24 0–24 73–74 1–74
20.77 (12.05) 23.82 (0.38) 20.45 (4.28) 73.82 (0.38) 44.43 (19.47)
(n = 22) (n = 15) (n = 22) (n = 15) (n = 22)
0–33 24 0–24 74 0–54
8.31 (10.88) 24 (0) 13.77 (7.34) 74 (0) 22.22 (17.52)
pically developing (grey) and DMD (black) subjects in the items I, J, K and
f the results after the age of 10.
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I, J and K, there was a marked overlap between the
typically developing and DMD cohort until after the age
of 10 years.4. Discussion
One of the aims of this cross sectional study was to
evaluate the reliability of the PUL in a multicentric
setting. Our results showed that, following standardized
training, the PUL has excellent interobserver and
intraobserver reliability.
We also wished to establish the earliest age when both
typically developing and DMD boys were able to
complete the assessment. Performing the PUL in
preschool boys, we conﬁrmed that the items included in
the assessment could be easily administered. Typically
developing children were consistently able to perform the
full scale with full total scores or one point less (73 or 74
out of 74) by the age of 5 years. In contrast, a proportion
of those younger than 5 had diﬃculties in completing
some items because of their hand and arm size that
restricted reaching and holding the bigger weights or
stacking cans from sitting. In the DMD cohort the
assessment was also easily completed by all the boys with
the ones younger than 5 also having the same diﬃculties
met by their peers because of hand and arm size. These
results would therefore suggest that the PUL is more
appropriate from the age of 5 years.
Not surprisingly, while in the typically developing
cohort the scores remained stable after the age of 5, in
the DMD cohort there was a steady deterioration. The
diﬀerence between the two cohorts was minimal before
the age of 8 and became wider with increasing age. In the
younger group the diﬀerence was mainly obvious at
shoulder level dimension, as DMD boys generally did not
achieve the same scores of their typically developing
peers and some proximal weakness could already be
detected even in a proportion of the patients who were
still ambulant. There was a steep fall in the shoulder level
scores between the ages of 9–16, with only a few boys
being able to achieve a score of 3 after this age.
As expected the changes at elbow and distal level
appeared at a later age, reﬂecting the proximal to distal
gradient of weakness observed in DMD.
In a previous study assessing the suitability of existing
measures, such as the Jebsen or the 9 hole peg test or
other measures not speciﬁcally devised for DMD, we
observed that a large proportion of boys older than
15 years had a clear ﬂoor eﬀect, scoring 0 on all the items
[8–10]. In the present study we were able to demonstrate
that the PUL is instead capable of measuring small distal
movements even in the older weaker DMD subjects.
These items assess the functional use of ﬁngers such as
lifting small weights or pointing, that relate to activities
of daily living, such as using a mobile phone, a computermouse or the wheel chair joystick that are very relevant
for this age group.
At the time of developing this version of the PUL we
decided to keep a number of items assessing diﬀerent
ﬁnger pinches as we wished to establish possible
diﬀerences in their scores due to diﬀerent levels of
weakness or contractures. In the DMD cohort some of
these items had similar scores (e.g. two and three ﬁnger
pinch, data not shown) or were passed in over 90% of
the cohort (e.g. place the ﬁnger on a diagram). A larger
data collection is in progress to perform Rasch analysis
in order to explore possible co-dependency and reduce
the number of distal items.
Another aim of this study was to establish the value of
timed items to avoid ceiling eﬀect. In the younger age
group however the timed results were similar in both
DMD and typically developing cohorts. The diﬀerence
was more obvious in the second decade but in that age
range there is no risk of ceiling eﬀect as few DMD boys
have full total PUL scores. The only timed item that
appeared to show some diﬀerences already in younger
boys was stacking heavy cans.
Our study provides for the ﬁrst time cross sectional data
using the PUL in a relatively large cohort of DMD with a
wide age range. The results suggest that the PUL can be
reliably used in a multicentric setting and is suitable in
patients from the age of 5 until adulthood, as it did not
show an obvious ﬂoor eﬀect even in the older patients.
As observed in other tests assessing other aspects of
function in DMD, such as the 6MWT, we also found a
wide variability in scores that was particularly true in the
8–14 years age range. The variability in this age range is
partly reﬂected by the level of ambulation with ambulant
boys having better scores than the non-ambulant ones
who are overall weaker. This however did not always
held true for individual cases as a number of
non-ambulant boys had similar PUL scores to the
ambulant patients.
The total scores allowed to observe the progressive
decrease in the whole cohort with age while the subscores
assessing the three major level dimensions clearly
indicated the proximal to distal gradient of loss of
function at diﬀerent ages. The timed items in contrast did
not appear to provide additional information.
Our data suggest that the assessment can be reliably
used in both ambulant and non ambulant Duchenne
patients in a multicentric setting and could therefore be
considered as an outcome measure for future trials.
Further studies collecting data in larger cohorts will
provide a better understanding of possible changes over
time and collect natural history data.
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